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Background: Anxiety disorders in children and young people are common and bring significant personal and societal
costs. Over the last two decades, there has been a substantial increase in research evaluating psychological and
pharmacological treatments for anxiety disorders in children and young people and exciting and novel research has
continued as the field strives to improve efficacy and effectiveness, and accessibility of interventions. This increase in
research brings potential to draw together data across studies to compare treatment approaches and advance
understanding of what works, how, and for whom. There are challenges to these efforts due largely to variation in
studies’ outcome measures and variation in the way study characteristics are reported, making it difficult to compare
and/or combine studies, and this is likely to lead to faulty conclusions. Studies particularly vary in their reliance on
child, parent, and/or assessor-based ratings across a range of outcomes, including remission of anxiety diagnosis,
symptom reduction, and other domains of functioning (e.g., family relationships, peer relationships). Methods: To
address these challenges, we convened a series of international activities that brought together the views of key
stakeholders (i.e., researchers, mental health professionals, young people, parents/caregivers) to develop recom-
mendations for outcome measurement to be used in treatment trials for anxiety disorders in children and young
people. Results and Conclusions: This article reports the results of these activities and offers recommendations for
selection and reporting of outcome measures to (a) guide future research and (b) improve communication of what has
been measured and reported. We offer these recommendations to promote international consistency in trial reporting
and to enable the field to take full advantage of the great opportunities that come from data sharing going forward.
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Introduction
Anxiety disorders are among the most frequent
mental health problems experienced by children
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and young people (CYP; i.e., youth under 19 years of
age), affecting around 6.5% of CYP worldwide
(Polanczyk, Salum, Sugaya, Caye, & Rohde, 2015).
Anxiety disorders in CYP are associated with current
social and academic adjustment difficulties, and the
development of other mental health problems and
adverse outcomes in critical life domains in adult-
hood (Asselmann, Wittchen, Lieb, & Beesdo-Baum,
2018; Essau, Lewinsohn, Olaya, & Seeley, 2014;
Lieb et al., 2016; de Lijster et al., 2018). The high
prevalence rates and the impact on current and
future functioning calls for effective interventions for
CYP with anxiety disorders.
Interventions to treat anxiety disorders in CYP
have been developed and evaluated in randomized
controlled trials (RCTs). Meta-analyses based on
multiple RCTs have shown that psychological ther-
apies, particularly cognitive behavioral therapy
(CBT), and pharmacological treatments, particularly
SSRIs (Ipser, Stein, Hawkridge, & Hoppe, 2009;
Walkup et al., 2008), are associated with substantial
decreases in anxiety over and above control condi-
tions in the short term. Although findings are some-
what mixed across studies, there is evidence, at least
for CBT, for durable changes at longer term follow-
up, and with positive outcomes on broader domains
(Gibby, Casline, & Ginsburg, 2017; Kreuze, Pijnen-
borg, de Jonge, & Nauta, 2018; Reynolds, Wilson,
Austin, & Hooper, 2012; Rith-Najarian et al., 2019;
Saavedra, Silverman, Morgan-Lopez, & Kurtines,
2010; Swan et al., 2018).
The first RCTshadbeendesigned to primarily study
efficacy of particular treatments. Although these
RCTs have enabled conclusions about efficacy, most
of them were not designed to draw clear conclusions
about the relative efficacy of different treatment
approaches and about which treatments work best
(and are most durable) for which CYP, for which
specific disorders or symptom clusters, and in which
settings (e.g., mental health institutions, research
settings, schools). This information is critical for
developments in understanding and practice and to
inform endusers, policymakers, and clinicians on the
effects they can expect from different interventions in
different contexts. However, attempts to address
these issues, for example through network meta-
analyses (Zhou et al., 2018) and through combining
individual patient data from multiple trials (e.g.,
Skriner et al., 2019), are limited by a lack of consis-
tency and clarity in how outcomes are measured,
administered, and reported. Earlier trials were also
limitedby a lack of guidance on reporting on trials and
the information provided in papers was quite hetero-
geneous. Such a lack of consistency in how trial
procedures are reported, limits replicability of studies
and the examination of potential treatment predic-
tors, mediators, and moderators.
Since the end of the 1990s, this state of affairs
improved somewhat following the development of the
CONSORT (Consolidated Standards of Reporting
Trials) Statement to enhance transparency and con-
sistency in reporting on RCTs (Begg et al., 1996;
Schulz, Altman, & Moher, 2010). Recently, an exten-
sion was published for reporting on social and psy-
chological interventions (Grant et al., 2018) to
supplement the more biomedical approach of the
original CONSORT statement. These guidelines pro-
vide an important framework and trial reporting qual-
ity appears to have improved since CONSORT was
published, including in RCTs for CYP with anxiety
disorders (e.g., James, James, Cowdrey, Soler, &
Choke, 2013; Reynolds et al., 2012; Warwick et al.,
2017). However, these general guidelines were not
designed to address issues that are age and/or condi-
tion-specific. For instance, across trials for CYP with
anxiety disorders, there is a broad range of ways in
which diagnostic outcomes, symptom measures, and
other secondary outcomes are used. Reports vary by
the informant (e.g.,parentorchild)andonwhatexactly
they are reporting on (e.g., comorbidity or functioning;
seesectionsbelowandWarwicketal.,2017).Similarly,
there are treatment characteristics inCYP that vary yet
have not been addressed in general guidelines, for
example, how and to what extent parents should be
involved in treatment. We require transparent and
consistent reporting on these characteristics in order
to inform clear guidance going forward.
This article addresses these issues by providing
recommendations for the selection and reporting of
outcome measures and treatment characteristics in
RCTs for CYP with anxiety disorders. Individual trials
need to specify the most relevant primary and sec-
ondary outcome measures to achieve trial-specific
aims, so it is not our intention to be prescriptive about
particular diagnostic interviews or questionnaires
that researchers should use. Instead, our aim is to
operationalize a small core set of key recommenda-
tions so that data can be measured consistently and
meaningfully combined, while also keeping it feasible
to report all the recommended features alongside any
trial-specific measures. Along with the core key rec-
ommendations,we formulatedadditional suggestions
that we encourage researchers to report on where
feasible. We also aim to outline the key issues to
consider when deciding which specific measures to
choose, and we make recommendations to ensure
clear and consistent reporting. It is important to note
that the recommendations were formulated as guide-
lines for reporting on clinical trials, and not for
routinely collecting outcomes in clinical practice (for
guidance on this instead see e.g., the standard
formulated by the International Consortium for
Health Outcomes Measurement (ICHOM); Working
Group on anxiety, depression, OCD and PTSD in
children and young people; ICHOM, 2019).
Method
Following discussions at multiple international meetings, we
organized a workshop prior to the annual conference of the
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European Association for Behavioural and Cognitive Therapies
(EABCT) in Sofia, Bulgaria, in September 2018. We invited
expert mental health professionals and researchers in the field
from across geographical regions and at varying career stages.
We identified four topics: (1) diagnostics, (2) anxiety symptoms,
(3) secondary outcomes, and (4) treatment characteristics.
Each topic was introduced within a plenary session followed by
discussion with either the entire group or subgroups, to reach
consensus and define recommendations. Our main goal was to
provide guidelines in terminology and to formulate a minimal
set of recommendations to enhance consistency in reporting
across trials. In the process, much discussion was devoted to
the distinction of topics that were regarded as ‘key recommen-
dations’ from topics that would be good or interesting, yet not
feasible to report on every trial. We formulated ‘recommenda-
tions’ (recommended to report) and ‘suggestions’ (encouraged
to report), respectively. Volunteers signed up to write a draft of
each topic in subgroups, using an online platform to share
documents. Additional experts who expressed interest in
joining but who were unable to attend the meeting were added
to the subgroups. All drafts were edited and integrated into one
full draft, which was then presented to a panel of patient
representatives and a panel of clinical professionals. Stake-
holder input was integrated in the second draft. The main
conclusions of the second draft were then presented at the
annual meeting of the Special Interest Group (childhood
anxiety) of the Association of Behavioral and Cognitive Ther-
apies (ABCT) in Washington DC in November 2018, where we
requested feedback and further input from three subgroups of
approximately 15 further participants. Some of those partic-
ipants then joined the consensus group and provided more
input, which was again edited and integrated into the final
manuscript.
In parallel with this process, we consulted key stakeholders,
aiming to establish broader views on measuring treatment
outcomes. We included parents and CYP with experience with
treatment for anxiety problems in the UK and conducted two
discussion groups with mental health professionals with
experience of assessing and treating child and adolescent
anxiety disorders in mental health institutions in the Nether-
lands and the UK. We asked each group their thoughts about
meaningful measures in the context of RCTs in anxiety
disorders in CYP.
Results
Stakeholder input
CYP feedback suggested that establishing a diagno-
sis was important at the start of treatment to
facilitate access to relevant information, increase
understanding, and to access support for the situ-
ation. However, CYP felt that the most important
outcome was generally ‘feeling better’, in combina-
tion with progress on individualized goals that could
be assessed regularly throughout the treatment. To
capture this, CYP suggested that it may be most
meaningful to assess changes in how anxiety
impacts the individual’s functioning. Short ques-
tionnaires with positively framed items on meaning-
ful aspects were preferred over long questionnaires
with multiple negatively framed items that they felt
could make them feel worse.
The parents agreed that a diagnosis was useful to
enable information seeking and understanding for
family members, and stressed the importance of
reducing symptoms and impairment in daily
functioning. Parents also highlighted their interest
in obtaining a more personalized ‘story’ of the
individual CYP incorporating the history and the
impact on the family beyond receiving a diagnosis
because they felt a diagnosis did not necessarily
reflect the full picture of the problem. Mental health
professionals and parents stressed the importance of
assessing anxiety symptom reduction as an impor-
tant outcome. They particularly prioritized change in
interference in daily functioning in various domains
including school, family, and peers.
Mental health professionals described the aim of
treatment as getting the CYP back on their develop-
mental trajectory (e.g., academic, social, activities).
Mental health professionals further valued the use of
individual or personalized treatment goals that are
specific to and meaningful for the child or family. For
example, for one family the most important outcome
following treatment from separation anxiety disorder
may be for the child to go to sleep independently,
whereas for another child, it may be to attend school
consistently and/or on time. Such personalized
treatment goals may also be broader than just
anxiety symptom reduction, for example, ‘taking
part in out of school activities’ or ‘spending more
time with friends’, following the family’s needs and
wishes. Professionals highlighted that parent and
CYP perspectives may be different and both are
important to create a full picture. They also noted
that, in some cases, a useful treatment outcome
could reflect the family’s confidence in managing
current and/or future anxiety problems, that is,
rather than full remission. We considered these
views when making our recommendations for report-
ing and for future measurement development.
Issues and guidelines
Diagnostic outcomes. Semi-structured diagnostic
interviews ((e.g. Anxiety Disorder Interview Schedule
for DSM-IV-Child and Parent Version (ADIS-C/P);
Schneider, Pflug, In-Albon, & Margraf, 2017; Silver-
man, Albano, & Barlow, 1996; Kinder-DIPS-OA)
have been most commonly used in trials of CYP with
anxiety disorders to assess a range of anxiety disor-
ders, common comorbid disorders, and associated
functional impairment. There is reasonable overlap
in the interview schedules’ content, but there can be
marked variation in the outcomes that are derived
and reported from these diagnostic interviews in
RCTS. Variations include absence/presence of a
specific diagnosis, the principal diagnosis, or all
diagnoses, the total number of diagnoses, the num-
ber/type of symptoms, and interference/severity
ratings (e.g., ‘Clinician Severity Ratings’; CSRs).
There is also variation in how these outcomes are
assessed, including whether child, parent, and/or
assessor report are used, how diagnoses and inter-
ference/severity ratings are assigned, and how a
composite summary is established. We outline below
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key considerations and recommendations to encour-
age greater consistency in reporting and assessing
diagnostic outcomes. Since the ADIS-C/P interview
is the most commonly used diagnostic interview, we
use examples that fit with this interview, but the
recommendations can be applied to reporting on
diagnostics derived from other interview schedules.
‘Remission’ outcomes. Remission, or absence of
anxiety diagnoses, is often the primary outcome in
child anxiety treatment trials (e.g., Silverman et al.,
1999; Spence, Donovan, & Brechman-Toussaint,
2000) and meta-analyses (e.g., James et al., 2013).
However, there is variation inhowremission isdefined
and reported (Warwick et al., 2017). Some studies
report the absence of the pretreatment principal
anxiety disorder (i.e., typically established as the
most interfering and, as such, may also be the most
salient problem for which the family seeks help). In
contrast, some other studies report the absence of a
subset of anxiety disorders (e.g., the disorders that
would have made a child eligible for the trial), the
absence of all anxiety disorders, or the absence of all
anxiety and nonanxiety disorders. Depending on the
researchaims, the type of treatment (e.g., whether it is
amultianxiety disorder-focused treatment (where the
treatment protocol can target a range of anxiety
disorders) or disorder-specific (where treatment tar-
gets one particular anxiety disorder), and available
resources, researchers may prioritize one remission
outcome over another. For example, where a treat-
ment targets a specific anxiety disorder (e.g., social
anxiety disorder or specific phobia), researchers may
be most interested in recovery from this target disor-
der. However, if the aim is to establish whether or not
treatment gains extend to other anxiety disorders,
recovery from all anxiety disorders will be the most
relevant outcome. Post-treatment and follow-up
assessment procedures also vary; in some cases, the
full structured diagnostic interview is administered,
but in others only anxiety disorders, or a subset of
anxiety disorders, or the pretreatment anxiety disor-
ders are assessed.
Consistency in reporting remission outcomes is
critical to allow data to be meaningfully compared
and combined across child anxiety treatment trials.
The high rate of comorbidity and overlap in symp-
toms among anxiety disorders in children and ado-
lescents (e.g., Kendall et al., 2010; Waite & Creswell,
2014) means outcomes may vary substantially
depending on which remission indices are used.
However, focusing exclusively on the pretreatment
principal diagnosis fails to consider the presence of
common comorbid anxiety diagnoses, or the emer-
gence of new anxiety diagnoses; and accurate differ-
ential diagnosis is reliant on a comprehensive
assessment of all anxiety disorders. Note that, in
line with DSM-5 classification, OCD and PTSD are
typically regarded as comorbid nonanxiety disor-
ders. We recommend that researchers assess all
anxiety disorders post-treatment and at subsequent
follow-ups (including those disorders that were not
present at pretreatment) for trials of multianxiety
disorder-focused anxiety disorder treatments. There
was some discussion on whether or not to recom-
mend reporting on all anxiety diagnoses in trials on
specific anxiety disorders, weighing the disadvan-
tages to the advantages. Perceived disadvantages
include the effort required and that the aim is not
necessarily for effects to generalize to all anxiety
disorders. Advantages mentioned were the consis-
tency and opportunities for comparisons across
trials. In conclusion, we recommend that research-
ers routinely report remission outcomes in terms of
both (a) absence of principal anxiety disorder diag-
nosis and (b) absence of all anxiety disorder diag-
noses, in trials of multianxiety disorder-focused
treatments and this is also encouraged for anxiety
disorder-specific treatments. Reporting on nonanxi-
ety comorbid disorders (such as depression) is
encouraged but was not regarded as key to the
minimal set of consistent variables to report on;
however, these are likely to be particularly important
considerations with increasing child age (Merikan-
gas et al., 2010), particularly as there is evidence
that anxiety disorders may be a gateway condition to
other mental health problems (e.g., Beesdo-Baum
et al., 2015; Kessler et al., 2012). To promote
consistent and transparent terminology when
reporting remission outcomes, we recommend
researchers use the template for reporting remission
outcomes in Table S1.
Child, parent, and clinician ratings in diagnostic
interviews. Structured and semi-structured diag-
nostic interviews typically include independent child
and parent interviews, with guidelines on proce-
dures for assigning diagnoses based on the combi-
nation of symptoms and associated interference/
severity ratings. However, trials vary in use of (a)
child and/or parent interviews; and (b) information
provided by one or more informant to assign and
report diagnoses and interference/severity ratings.
Administering independent child and parent inter-
views is standard practice and joint parent and child
interviews can be more acceptable in specific con-
texts (Ishikawa et al., 2019). However, there are
circumstances where the child or parent interview
only is used, for example, because of the specific
sample, the purpose of the trial, the age of partici-
pants, available resources, or participant burden.
Information collected from child and/or parent
interviews, together with assessor ratings, is then
used and combined (in various ways) to assign
diagnoses and interference/severity ratings.
Table 1 details descriptors of each potential repor-
ter combination, together with the associated pro-
cess for assigning diagnoses/interference ratings.
Given the wide variability in how researchers have
made decisions about diagnostic outcomes, we
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recommend that researchers use these descriptors
to detail how diagnoses/interference ratings were
assigned, and to indicate which reporter or combi-
nation of reporters is reported to promote trans-
parency and clarity. We recommend that, wherever
possible, researchers report ‘consensus composite
ratings’ based on child and parent interviews, that is,
assessor ratings assigned following discussion with
a supervisor/independent clinician or the study
team to derive consensus. Alternatively, where only
one interview is used, we suggest the corresponding
‘consensus rating’ is used. Researchers may also
choose to report diagnoses/interference ratings
based on other reporters (e.g., child report, parent
report), but this information should be additional to
consensus ratings.
Where independent child and parent interviews
are used, a key consideration is how best to combine
information from these two interviews to assign
diagnoses. This presents a challenge for researchers,
given the common discrepancies between reporters,
and particularly that the extent of the discrepancy
may be influenced by clinically relevant factors,
including child age, gender, ethnicity, socio-eco-
nomic status, social desirability, problem type, par-
ent mental health, and aspects of the parent–child
relationship (e.g., De Los Reyes & Kazdin, 2005).
While other approaches have been suggested for
dealing with the challenge of informant discrepan-
cies (e.g., De Los Reyes & Kazdin, 2005), our primary
aim in this paper is to promote consistency in trial
reporting so we have prioritized methods which are
currently commonly used and that can be followed
systematically and minimize potentially arbitrary
approaches. In this way, a substantial degree of
unknown variance may be reduced, precisely the
reason why the field has long moved away from using
unstructured clinical interviews. As such, we rec-
ommend that researchers continue to follow stan-
dard guidelines (as outlined in the ADIS-IV-C/P, and
recent ADIS-5-C/P, manuals for instance Silverman
& Albano, 2020) and apply the ‘OR-rule’, that is, a
diagnosis is assigned if the symptoms are reported
by either the child OR the parent. This is consistent
with recommendations made by Comer and Kendall
(2004) who concluded that ‘employing the ‘OR- rule’
increases the likelihood that all clinical cases are
included. Given the poor diagnostic agreement iden-
tified among parents and children, this rule seems
more practical than the more conservative ‘AND-
rule’, in which a disorder is considered present only
if the reports of all informants meet criteria for that
disorder. If a different approach is taken, it is critical
that researchers explicitly report this and describe
their approach, and this should be couched in
further research to determine the potential impact
on findings (in terms of reliability and reported
outcomes) of taking an alternative approach.
While we advocate the use of the ‘OR- rule’ in order to
promote consistency, it is important to reach the most
parsimonious diagnostic conclusion – in other words,
the most appropriate single diagnosis should be
Table 1 Descriptors for reporting how symptom criteria and interference/severity ratings were assigned to inform diagnoses and
which reporter combination was used
Reporter/reporter
combination Assigning symptom criteria Interference/severity rating
Child report Symptoms reported by child Interference rating given by child
Parent report Symptoms reported by parent Interference rating given by parent
Combined child and
parent report
Symptoms reported by child OR parent Higher interference rating of the two (child or parent)
Assessor rating based on
child interview
Based on child-reported symptoms and
clinical judgment of the assessor
Clinician interference/severity rating (CSRc) based on child-
reportedinterference rating and assessor judgment
Assessor rating based on
parent interview
Based on parent-reported symptoms
and clinical judgment of the assessor
Clinician interference/severity rating (CSRc) based on
parent-reported interference rating and assessor judgment
Assessor composite
rating based on child
and parent interviews
Based on child OR parent reported
symptoms and clinical judgment of the
assessor
Clinician composite interference/severity rating (CSRc)
derived from (a) assessor rating based on child interview
and (b) assessor rating based on parent interview; higher
CSR of the two
Consensus rating based
on child interviewb
Based on child-reported symptoms and
assessor and supervisor judgment
Consensus clinician interference/severity rating (CSRc)
based on child-reported interference rating, and assessor
and supervisor judgment
Consensus rating based
on parent interviewb
Based on parent-reported symptoms
and assessor and supervisor judgment
Consensus clinician interference/severity rating (CSRc)
based on parent-reported interference rating, and assessor
and supervisor judgment
Consensus composite
rating based on child
and parent interviewsa
Based on child OR parent reported
symptoms and assessor and supervisor
judgment
Consensus clinician composite interference/severity rating
(CSRc) derived from (a) consensus rating based on child
interview and (b) consensus rating on parent interview;
higher CSR of the two
aRecommended.
bRecommended where only child or parent interview is administered.
cCSRs are used in the ADIS-C/P, for other structured diagnostic interviews, the corresponding clinician/assessor-rated
interference/severity ratings should be used.
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applied to explain essentially the same symptoms. For
example, a childmaymeet diagnostic criteria for social
anxiety disorder based on the child report and criteria
for generalized anxiety disorder based on the parent
report.However, if theexcessiveworries reportedby the
parent are exclusively related to fear of embarrassment
orsocial evaluation,andnotaccountedbymoregeneral
worries about control, predictability, or negative affect,
then the assessor should consider assigning a social
anxiety disorder diagnosis only.
Clinician Severity Ratings (CSRs). Themost widely
reported interference/severity ratings derived from
structured diagnostic interviews are CSRs. CSRs are
assigned for each individual anxiety (and comorbid)
diagnosis and, as detailed in Table 1, are generated
by assessors for diagnoses based on (a) child report,
(b) parent report, and (c) combined child and parent
report. However, in addition to differences in how
information from different reporters is combined,
there is further variation in how CSRs are used
across child anxiety treatment trials. CSRs are
intended to provide a measure of severity and inter-
ference (Silverman et al., 1996), but this is not
applied consistently. Our discussions indicate that
some research groups use CSRs as a measure of
severity, others focus on interference, and others use
a conglomerate of the two. To help ensure CSRs are
assigned consistently across trials, we urge research-
ers to continue to adhere to the guidance provided in
interview schedules on assigning CSRs (e.g., (Silver-
man & Albano, 2020; Silverman et al., 1996).
CSRs are summarized and reported in different
ways, including, for example, the CSR for the pre-
treatment principal anxiety diagnosis, the sum of
CSRs across anxiety diagnoses, or the average CSR
across all anxiety diagnoses. There are also issues
related to whether the entire continuum of CSRs is
reported. Research groups differ in whether they
assign and report CSRs across the whole scale or only
for those children who would meet diagnostic criteria
by virtue of having the required symptoms and a
composite CSR of four or more (on a 0–8 scale). If
ratings are reported dimensionally from4–8, but then
are assigned a 0 for all ratings below 4, the resulting
scale is a combination of categorical and dimensional
scales which raises questions about the appropriate
statistical analyses. Summing and averaging CSRs
across disorders can also be problematic.
Reporting CSRs can nevertheless provide impor-
tant information about the degree of impairment
associated with disorders that are present following
treatment, both where the pretreatment principal
anxiety disorder persists, or is in partial remission
(CSR = 1–3), and where comorbid disorders remain
or emerge. Given the issues raised above regarding
the distribution of CSR data, we recommend that
CSRs are primarily used to inform decisions about
diagnoses; however, if they are reported, we encour-
age researchers to include reporting of this data in
its categorical form, that is, to report the frequencies
of participants assigned to each CSR for (a) the
pretreatment principal anxiety disorder, and (b) the
most-impairing disorder at each time point.
Table 2 provides a summary of the recommenda-
tions for reporting on diagnostic outcomes. Criti-
cally, across diagnostic outcomes, it is important
that researchers report on how assessors were
trained and to what criterion, the inter-rater relia-
bility that was established, and the nature of super-
vision was conducted and how reliability was
ensured throughout the trial.
Continuous measures of reported symptoms and
functional interference
This section focuses on important considerations in
the selection of measures and respondents to assess
outcomes in terms of (a) anxiety symptoms and (b)
interference caused by anxiety.
Constructs: What to measure?. Different assess-
ment measures have been designed for different
contexts and purposes, such as screening in the
general population, early identification of those at
risk, clarifying the nature, severity and impairment
associated with clinical disorders, and assessing the
impact of interventions. Below we focus on a minimal
set of key recommendations of measures of treat-
ment outcome.
Anxiety symptoms. Historically, treatment trials
have most commonly including CYP with various
Table 2 Summary of Recommendations regarding diagnostic
outcomes
 Report on absence of pretreatment principal
anxiety disorder diagnosis at each time point.
 For multi-anxiety disorder-focused treatments
(and where possible for disorder-specific treat-
ments), assess all anxiety disorders at each time
point and report on the absence of all anxiety
disorder diagnoses.
 Use the template for reporting remission out-
comes provided in Table S1.
 Use descriptors provided in Table 1 to provide
clarity on how diagnoses and interference/
severity ratings were assigned and which repor-
ter combination was used.
 Where possible, report consensus composite
ratings based on child and parent interviews.
 Where independent child and parent interviews
are administered, use the ‘OR-rule’ to assign
diagnoses (or report if using another approach),
but be mindful to ensure the same symptoms are
not assigned to multiple diagnoses.
 Follow guidance provided in interview schedules
when assigning CSRs in order to assign diag-
noses and report as categorical data.
2020 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
Child and Adolescent Mental Health
6 Cathy Creswell et al.
anxiety disorders and have used ‘multianxiety disor-
der-focused’ treatment protocols that can be applied
across a range of disorders (e.g., Ginsburg et al., 2011;
Hudson et al., 2009; Kendall, Hudson, Gosch, Flan-
nery-Schroeder,&Suveg,2008;Thirlwall et al., 2013).
Appropriately therefore, the bulk of studies conducted
in this area have included measures of anxiety symp-
toms that cover symptoms of the major anxiety disor-
ders specified in the DSM, for example, separation
anxiety disorder, social anxiety disorder, generalized
anxiety disorder, specific phobia, and panic/ agora-
phobia. This approach has been valuable in allowing
the comparison of results across clinical trials. Scales
covering the different anxiety disorders have the
advantage that they can report on both a broad range
of anxiety symptoms as well as symptoms of specific
anxiety domains, thus leaving the option of evaluating
and comparing the impact of broad and specifically
targeted treatments on broad and specific subscales.
For instance, one could evaluate the impact of amulti-
anxiety disorder-focused CBT program on total anxi-
ety symptoms as well as on social anxiety symptoms
specifically, and compare that to the broad and
specific impacts of a social anxiety disorder-focused
treatment. As such, we recommend the inclusion of a
multidimensional measure of anxiety symptoms that
includes a total score for anxiety in general, evenwhen
the trial targets a specific anxiety disorder. For an
overviewof specificmeasures thatmaybeused for this
purpose (at particular ages), we refer to the recent
review by Spence (2018).
Where a study focuses upon the treatment of a
specific anxiety disorder, we recommend including a
measure that focuses on symptoms of the specific
disorder concerned, in addition to a broader mea-
sure of anxiety. Such a focused measure may
potentially be a subscale of one of the multidimen-
sional anxiety measures described above as long as
there is evidence that it is a psychometrically sound
measure of the specific construct of interest (e.g., see
Reardon, Spence, Hesse, Shakir, & Creswell, 2018).
Interference associated with anxiety symp-
toms. We recommend that a measure of the level
of day-to-day interference associated with anxiety is
included and reported in clinical trials due to both
the emphasis on the importance of this as a mean-
ingful outcome to CYP, parents, and clinicians, and
also based on recent evidence suggesting that inter-
ference measures align better with diagnostic out-
comes than measures of symptoms (Evans,
Thirlwall, Cooper, & Creswell, 2017). While there
are specific measures of interference caused by
anxiety (e.g., the Child Anxiety Impact Scale-CAIS
(Langley, Bergman, McCracken, & Piacentini, 2004);
the Child Anxiety Life Interference Scale – CALIS
(Lyneham et al., 2013); the Child Sheehan Disability
Scale adapted for child anxiety (CSDS; Whiteside,
2009)) other assessment tools (e.g., the Pediatric
Anxiety Rating Scale (PARS; RUPP Anxiety Study
Group, 2002) typically produce one total scale for
anxiety covering various aspects including severity
and interference of anxiety symptoms (as well as
frequency, distress, and avoidance). We recommend
that if such a measure is used, the item level data are
also reported, and not only the ‘total anxiety’ score
that conflates symptoms and interference.
Other considerations in selecting parent and child
report measures
Psychometric properties. First and foremost, when
choosing which measures of the above constructs to
include ina trial, thepsychometric strength (e.g., test–
retest reliability, internal consistency, construct
validity) of the measure is paramount. Importantly,
the measure should be able to discriminate between
clinical and nonclinical levels of anxiety and be
sensitive to treatment gains in children and young
people. Having said this it is important to highlight
that there are limited data on the sensitivity and
specificity of clinical cutoff points for determining
diagnostic status on the basis of child anxiety ques-
tionnaires (for exceptions see e.g., DeSousa, Salum,
Isolan,&Manfro,2013;Evansetal., 2017;Rynnetal.,
2006). Furthermore, typically, measures have been
developedwith children agedbetween8and17 years,
from white, two-parent families of relatively high
socio-economic status, and we have limited knowl-
edgeof the relevanceandsensitivityof thesemeasures
across cultures, minority groups, and age/gender
sensitivity. While examples of culture-bound anxiety
syndromes have been identified in young adults (e.g.,
Essau, Sasagawa, Chen, & Sakano, 2012), studies to
date have suggested that commonly used measures
for children are robust across particular ethnic
groups (e.g., Pina, Little, Knight, & Silverman, 2009;
Skriner&Chu, 2014). Future research should further
focus on increasing knowledge of applicability of
questionnaires to children and families who do not
fall into this narrow demographic.
Reporting. There is considerable inconsistency
between trials in what is reported with respect to
continuous measures. The results should be pre-
sented in sufficient detail to enable inclusion of
studies within meta-analyses based on mean scores,
standard deviations, and number of informants at
each time point for each condition. Given significant
variability in the availability of normative data for
different child anxiety measures, and variations
between age and sex, we recommend that research-
ers report mean raw scores and standard deviations
rather than standardized scores (such as T-scores).
With the above limitations in mind, we encourage
future research to also show change from pre- to
post-treatment (and follow-up) relative to the clinical
cutoffs to provide relevant information to inform
decision making for families, clinicians, and policy-
makers.
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Informants. Parent–child agreement on anxiety
symptoms is low to moderate (Popp, Neuschwander,
Mannstadt, In-Albon, & Schneider, 2017). Infor-
mants disagree due to the varied perspectives on
the child’s experience across different contexts
(Kraemer et al., 2003), although this varies with
child age (Silverman & Eisen, 1992). As a result, the
use of multiple informants (child, parent(s), clini-
cian, and teacher) should be carefully considered
when conducting youth anxiety research. With
respect to parental report, although including two
parents increases the richness of perspective due to
potentially different views (e.g., Moreno, Silverman,
Saavedra, & Phares, 2008), it often leads to high
levels of missing data for one parent and increases
the number of analyses reported in the trial papers
(Hudson et al., 2014). The low to moderate agree-
ment between parents on youth anxiety symptoms
(e.g., Fjermestad, Nilsen, Johannessen, & Karevold,
2017; Villabø, Gere, Torgersen, March, & Kendall,
2012) also means that combining data from parents
is not recommended as it leads to a potential loss of
valuable information and makes interpretation diffi-
cult. Therefore, as complete data sets from all
parents or caregivers are not possible or practical,
we recommend prioritizing a primary caregiver and,
importantly, ensuring consistent data collection
from that reporter a each time point within the trial.
Teacher report may provide valuable insight into a
child’s functioning at school, especially for children
at primary school level where individual teachers
typically have a high level of contact with individual
children (e.g., Reardon et al., 2018). However,
changes in teachers from year to year, together with
multiple teachers being responsible for the child with
differing depth of knowledge of the child’s symptoms
and interference, particularly in the high school
years, can make use of teacher report within and
across clinical trials problematic. Thus, because of
these issues and concerns, we are not including
teacher report in our list of key recommendations for
clinical trials.
An important issue arising from the inclusion of
multiple informants is resolving discrepancies in the
data they provide with respect to outcome. For
example, data from one informant (e.g., primary
caregiver) may demonstrate significant change fol-
lowing treatment while another (e.g., child) may not.
We recommend that researchers always prespecify
which reporters will be prioritized (if any). For
example, although Weisz et al. (2017) showed that
treatment effect sizes did not differ according to the
type of informant on anxiety symptoms, a number of
studies with preadolescent children have failed to
show treatment effects on child-reported anxiety
measures in the presence of significant change on
diagnostic outcomes and parent report (e.g., Rapee
et al., 2017). In line with this, it has been found that,
at least for preadolescent children, parent report is
more often consistent with diagnostic outcomes
(Evans et al., 2017). As such, for studies with
preadolescent children, we encourage researchers
to prioritize parent report, to maximize consistency
across studies.
Development and age. There are considerable
developmental differences across childhood and
adolescence, and symptom measures may be more
or less suitable for specific age groups (see also
Spence, 2018). Indeed, there is a lack of well
validated self-report measures for children under
the age of 8 years, with studies most typically relying
on parent report for this age group (e.g., Rapee et al.,
2005), and, as noted above, for preadolescent chil-
dren, parent report appears to more closely align
with clinician assessments (Evans et al., 2017).
Within trials, participants may cover age groups
with marked developmental differences and assess-
ments may also be conducted at time points between
which there may have been substantial developmen-
tal shifts. The challenge for researchers is how to
achieve a balance between consistency in measure-
ment use within (and between) trials and ensuring
that age-appropriate measures are used. The most
important consideration is that age-appropriate
measures are used at each assessment point, so
researchers must select measures that are appro-
priate for their whole participant age-range at the
outset of the study (and many questionnaire mea-
sures of anxiety have been validated across fairly
wide age ranges). Where follow-up assessments are
being administered sometime after the initial assess-
ment, it is possible that different questionnaire
measures will need to be used (e.g., if adolescents
have become adults). One example of how that has
been managed in previous studies comes from
Saavedra et al. (2010) where both youth and adult
measures were administered in parallel at all assess-
ment points, and then, developmentally sensitive
scale scores were generated based on item response
theory models. However, currently little is known
about the factorial (in)variance of measures with age
or development, or indeed with a range of other
characteristics that may influence responses to
these questionnaires (though there are exceptions,
e.g., Glod et al., 2017; Pina et al., 2009). Going
forward, further studies of the factorial (in)variance
of our commonly used scales are required to gain a
greater understanding of how demographic and
other characteristics affect responses.
A summary of the recommendations for reporting
on continuous measures of symptoms and func-
tional interference is given in Table 3.
Reporting on sample and treatment characteristics:
specific considerations for trials of treatments for
CYP with anxiety disorders
Sample and treatment characteristics should be
provided in sufficient detail to allow treatment and
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study replication, as well as to enable meaningful
comparison of effects between trials and treatment
types and to facilitate dissemination of effective
interventions. Guidelines now exist for the reporting
of trial characteristics however, in addition to the
detailed reporting required by the CONSORT and
CONSORT-SPI statements (Grant et al., 2018), there
are several factors specific to CYP anxiety interven-
tion trials that require consideration and for which
we provide reporting recommendations here. We
recognize that the recommendations and sugges-
tions for reporting that follow provide a lot of detail
about the interventions, which would traditionally be
beyond what could be reported in a journal article.
However, with growing use of supplementary mate-
rials by journals, the routine provision of this infor-
mation will improve access to critical data for
making comparisons across treatment studies and
integrating data across treatment studies.
Sample characteristics. As highlighted by Warwick
et al. (2017), further research is required to deter-
mine applicability of intervention effects across dif-
ferent participant groups and to detect potential
moderators of treatment outcome. However, to facil-
itate such evaluations, it is imperative that research-
ers provide detailed pretreatment demographic and
clinical characteristics of the sample in the context of
the intervention. Specifically, we recommend that
researchers report on the following baseline demo-
graphics: sex and/or gender (n, %), and age (range,
mean, SD). We also encourage researchers to report
on family living arrangements, ethnicity or country of
birth, and socio-economic status; however, we rec-
ognize that there will be regional variations in how
these data are collected and interpreted, so we
encourage use of national standards for collecting
and reporting. We recommend researchers report on
principal anxiety disorder at baseline, the mean and
range of the number of comorbid anxiety disorders,
and the frequency of each anxiety disorder (e.g., % of
children meeting criteria for social anxiety disorder
as a comorbid disorder). Moreover, we encourage
reporting of the number of comorbid (nonanxiety)
mental health disorders and frequency of each
disorder.
Treatments: contextual, structural, and content
characteristics. Recent meta-analyses have identi-
fied specific directions for future child anxiety inter-
vention research (e.g., James et al., 2013; Reynolds
et al., 2012), highlighting the need for study designs
and reporting to address questions about how treat-
ments work, for whom, how to adapt treatments for
different contextual situations, and how treatments
can be provided in the most cost-effective way
(Seligman & Ollendick, 2011). Combining data from
across trials can help to address some of these
questions; however, this requires explicit reporting
of what the different interventions include and about
the context in which the interventions were con-
ducted. This should include a description of the
contextual characteristics (target population(s), the-
ory, empirical evidence; see Table S2), structural
characteristics (dose/number of sessions, frequency,
sequence, modality, mode of delivery; see Table S3)
and content (treatment techniques and steps; see
Table S4 for an example). If separate treatment
elements are delivered to children, adolescents, and
parents, specific information should be provided for
each element. We recognize that different interven-
tion approaches are required for young people of
different ages and that this may be evidenced
through different treatment content, delivery modes,
treatment structure, and levels of parental involve-
ment (if any). For this reason, we recommend that
when age-specific treatments are provided within a
trial, treatments are described separately and with
sufficient contextual detail to allow effective compar-
ison and understanding. While these issues all
clearly apply to psychological interventions, they
also apply to the support that is provided alongside a
pharmacological intervention and should also be
reported in these contexts.
When describing treatments, particular attention
should be paid to describing parental involvement.
Recent meta-analyses have looked at the effect of
including parental involvement in CBT for children
with anxiety disorders, with some finding no bene-
ficial effect of parental involvement (e.g., Lebowitz,
Marin, Martino, Shimshoni, & Silverman, 2019;
Vigerland et al., 2016), and other finding better
Table 3 Summary of recommendations for continuous mea-
sures of reported symptoms and functional interference
 Include a multidimensional measure of anxiety
symptoms that provides a total score on anxiety
symptoms as well as subscales for symptoms of
specific anxiety disorders, even when the trial
targets a specific anxiety disorder.
 Include a measure of target symptoms where
relevant (e.g., include social anxiety symptoms
measure, if social anxiety disorder is the target of
the treatment; ensuring that this is psychomet-
rically reliable and valid for the specific target).
 Include a measure of interference or impact
caused by anxiety, separate from anxiety symp-
toms.
 Report mean raw scores and standard deviations
and number of informants at each time point, for
each measure and for each condition.
 Choose measures that are age-appropriate at
each time point.
 Report separate parent and child-reported mea-
sures.
 Report data from a consistent primary caregiver.
 Prespecify measures including whether results
based on particular reporters will be prioritized.
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long-term outcomes than when CBT is conducted
with parents alongside child treatment sessions
(Kreuze et al., 2018; Manassis et al., 2014). These
mixed findings are hard to fully understand given the
great variation in the type of and extent of parental
factors targeted in treatment studies. Some treat-
ments, for example, are solely delivered to or via
parents (e.g., Cobham, 2012; Lebowitz et al., 2019;
Thirlwall et al., 2013). To overcome this problem
going forward, special attention must be paid to
clearly describing the involvement of parents in
treatment, and how this may differ where trials
include, for example, both children and adolescents.
If there is a separate intervention for parents (e.g.,
workbook, parent sessions, online material), this
should be described in detail and separately using
the columns of the templates in Table S3. Specifi-
cally, we recommend that intervention protocol
descriptions are presented for all versions of the
treatment delivered (e.g., reflecting variations for
participants of different ages) and capture the num-
ber and frequency of parent sessions, parent involve-
ment in home exercises, presence of parents during
child treatment sessions, whether treatment
involved the presence of one or two parents, strate-
gies for providing information to parents in sepa-
rated families, and mode of delivery for parents.
Even when there is no specific treatment content
for parents, we recommend researchers report on
any planned interactions with parents that may
represent active treatment components. For exam-
ple, parents might receive psychoeducation together
with the child, be involved as a ‘therapist/coach’ for
homework purposes, be involved in exposure, or be
allowed to have separate contact with the therapist
during treatment, all of which may have an impact
on the child’s adherence and parental management
of anxiety. We recommend that this detail is reported
in line with the templates provided in Table S3.
Treatments: content characteristics. RCTs of
interventions for child and adolescent anxiety disor-
ders tend to focus on ‘treatment packages’. For
example, CBT, the most extensively evaluated treat-
ment for child anxiety disorders, typically consists of
multiple strategies or components, the most com-
mon components being exposure (included in 88% of
treatment packages), cognitive techniques (62%),
relaxation (54%), psychoeducation (42%), and mod-
eling (34%) (Higa-McMillan, Francis, Rith-Najarian,
& Chorpita, 2016). Programs targeting anxiety dis-
orders, on average, contain six to seven strategies,
with 29 different CBT strategies described in 27
studies (Frechette-Simard, Plante, & Bluteau, 2018).
These findings highlight that treatment packages
vary considerably in content, although this is not
always clear from the research papers. In addition,
treatment packages often offer treatment in a speci-
fic sequence and dosage and with multiple
modalities. As noted above, the content of parental
components also often varies considerably. For
example, the meta-analysis by Manassis et al.
(2014) highlighted potential differences in the roles
of contingency management, transfer of control, and
family functioning in parent focused components of
treatments for child anxiety disorders.
We recommend that the content of the treatment
studied in an RCT should be described in terms of all
treatment components per session, separately for
the child and parent components. The template in
Table S4 provides an example of such a description
of the content of the treatment(s). Furthermore,
where researchers have used an adapted existing
treatment packages for a specific (e.g., cultural)
context, any modifications and adaptations should
be reported explicitly (e.g., translation; tailoring of
terms; adding, deleting, or reordering elements;
Stirman, Miller, Toder, & Calloway, 2013).
Dosage of treatment received. It is important to
report the dose of treatment actually received by
participants in trials evaluating both psychophar-
macology and psychotherapy. Regarding medica-
tion, CONSORT provides guidelines on how to
report on a drug intervention (i.e., ‘the drug name,
dose, method of administration (such as oral, intra-
venous), timing and duration of administration,
conditions under which interventions are withheld,
and titration regimen if applicable’; Moher et al.,
2010) and further, specific recommendations
regarding childhood anxiety disorders do not seem
necessary. However, in child and adolescent anxiety
psychotherapy trials, meta-analyses have revealed
much variation in how the actual dose of treatment
received is reported (James et al., 2013) with partic-
ular gaps in reporting of the actual number of
sessions ‘attended’ or ‘received’, or time duration
(i.e., number of weeks) over which sessions were
completed. This can lead to misconceptions about
intervention dose and associated effects. Indeed,
there is emerging evidence that some delivery modes
(e.g., online programs) are associated with slower
completion of treatment sessions (Jolstedt et al.,
2018; March, Spence, & Donovan, 2008; Spence
et al., 2011; Vigerland et al., 2016) and that,
sometimes, treatment could be shortened in
response to subject characteristics such as anxiety
severity (Pettit, Silverman, Rey, Marin, & Jaccard,
2016). As such, we recommend that researchers
detail actual intervention uptake by participants.
That is, the average number of sessions and time
spent in sessions actually attended or received by
(both child and parent) participants at the post-
treatment or later follow-up assessments should be
reported as well as the actual total treatment dura-
tion (weeks) using a template such as that in
Table S5. If applicable, the received treatment
dosage at follow-up may be provided separately, for
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example, in the context of online interventions where
sessions may continue after the post-treatment (or
follow-up) assessment. Note that the current recom-
mendation only includes a quantitative evaluation
(how many sessions or hours were received). In
addition and if feasible, it may be fruitful to also
engage in more in depth evaluations of adherence
(e.g., McLeod et al., 2019).
Given the variations in the treatment components
employed in child and adolescent anxiety interven-
tions, it has been difficult to accurately identify key
active components. As such, we also encourage
researchers to provide information on the proportion
of participants adhering to specific treatment com-
ponents (e.g., exposure, relaxation; for an example
see McLeod et al., 2019), as well as on additional
strategies that were delivered that were not detailed
in the protocol. Such reporting has become partic-
ularly relevant in recent times with the emergence of
new treatment modalities such as online delivery,
within which detailed analytics are available regard-
ing participation in treatment (e.g., Jolstedt et al.,
2018). Subsequently, there is a unique opportunity
to understand which components and modalities are
most acceptable and effective for child and adoles-
cent anxiety disorders.
Treatment and hidden time. Both ‘hidden’ and
‘unplanned’ time is commonly encountered in child
and adolescent anxiety treatment trials (e.g.,
amount, content and delivery mode of preparation,
administration, supervision, liaising with schools or
teachers, conducting motivational interviewing with
parents to enhance engagement, crisis manage-
ment). We realize that many of these aspects vary
as a function of local customs and therapist experi-
ence. Nevertheless, collecting and describing these
aspects will be a good start to obtain insight into the
real-life costs of implementing treatments. We sug-
gest that the amount of hidden time is presented
using the template provided using the template of
Table S6. Specification of how potential missing
sessions were replaced is also encouraged, for
example, if missing a group-session resulted in
additional therapist time through an individual
face-to-face session.
Table 4 provides a summary of the recommenda-
tions on reporting on sample and treatment charac-
teristics.
Discussion
We identified consensus recommendations to sup-
plement standard guidelines for reporting on treat-
ment trials focused on child and adolescent anxiety
disorders to enable international consistency and to
facilitate comparison across trials. Our recommen-
dations were influenced by the views of CYP, parents
and professionals who particularly highlighted the
importance of measures of interference or
impairment caused by anxiety. This is a key compo-
nent of any diagnostic assessment, however, in
reflection of these views, we recommended that child
and parent-reported interference measures are
obtained in their own right. Of note, CYP, parents,
and professionals also value the assessment of goals,
highlighting an area for future measurement devel-
opment and evaluation going forward (for example,
through validation of measures such as the Goals
Based Outcomes (e.g., Law & Jacob, 2015) in the
context of treatment of child and adolescent anxiety
disorders). Finally, stakeholders highlighted the
importance of measures not being overly lengthy,
feeling relevant, and not being overly negatively
framed. We highlight these issues as ongoing chal-
lenges for the field. In terms of reducing burden,
going forwards there is clearly great potential for the
use of online assessments, algorithms, and mea-
surement of wider variables (e.g., through activity
monitoring) to both increase efficiency of assessment
and to enable more consistent reporting across
trials.
When making choices between recommendations
and suggestions we decided to discard those con-
structs that deserve a more extensive assessment
than we could recommend for all trials, which means
that particular areas that will often be worthy of
assessment, such as broader health related quality
Table 4 Summary of recommendations on reporting on sam-
ple and treatment characteristics
 Report on the following baseline demographics:
sex and/or gender (n, %) and age (range, mean,
SD).
 Report on principal anxiety disorder at baseline
(i.e. the most interfering anxiety disorder), the
number of comorbid anxiety disorders and
number of each anxiety disorder.
 Provide detailed description of treatment protocol
including contextual characteristics and struc-
tural characteristics, both for child and parent
interventions. We encourage researchers to use
the templates provided in Tables S2 and S3.
 Provide a detailed description of the content of
the intervention (focus and components per ses-
sion, separately for child and parent interven-
tions). We encourage researchers to use the
template provided in Table S4.
 Report on participant received dosage of struc-
tural elements of the intervention. We encourage
researchers to use the template provided in
Table S5.
 Report on planned and unplanned therapist/
treatment delivery time, including deviations
from protocol and additional active treatment
occasions. We encourage researchers to use the
template provided in Table S6.
2020 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
Child and Adolescent Mental Health
Trial reporting for child and adolescent anxiety disorders 11
of life and age-appropriate functioning in different
domains (e.g., school, home, hobbies, peers) which,
while encouraged, are not ‘recommended’. We also
did not make recommendations where issues are
already well covered by CONSORT guidelines and
where issues are not specific to reporting in the
context of treatment trials for CYP with anxiety
disorders, such as reporting on treatment integrity,
or on adverse effects of treatments.
Despite our attempts to retain a focused list of
recommendations, we have recommended that
reports are obtained from multiple informants, in
particular, clinicians, CYP and primary caregivers.
Taking this further, Rith-Najarian et al. (2017)
recommend, and we concur, that to demonstrate
treatment efficacy, significant effects should be
found with data gathered from more than one
reporter (e.g., clinical assessors and primary care-
giver and/or adolescent). Thus, we recommend
researchers include data from the reports of clinical
assessors’ as well as both children and parents and
state, a priori, which reporters will be prioritized in
drawing conclusions.
We also recommended that researchers provide
detailed information on the treatment that was
provided, including, global treatment components,
their dosage, and sequence. The option to include
supplementary materials alongside journal papers
means that this sort of information can now be
provided as standard. As a next step, it may be
important to use more comprehensive standardized
reporting templates to describe the details of treat-
ment components or techniques (e.g., cognitive
restructuring, problem solving, exposure) that are
used in a treatment protocol (e.g., Bodden, Nauta,
Kuijpers, Stone, & Stikkelbroek, 2016; Chorpita,
Becker, Daleiden, & Hamilton, 2007; Chorpita &
Daleiden, 2009). Such a taxonomy of treatment
contents would allow for consistent definitions and
descriptions of components (e.g., name (e.g., expo-
sure), definition (e.g., exposing the client to the
anxious situation or object in vivo or in imagination),
rationale (e.g., rationale based on habituation, self-
efficacy, inhibitory learning, etc). Such detailed
reporting would also facilitate integrated analyses
of processes of change and recovery including those
relating to mediational processes (e.g., Silverman
et al., 2019) and differential patient trajectories (e.g.,
Skriner et al., 2019).
It is important to highlight that the aim of the
current paper is to increase consistency in reporting
in clinical research trials, and some of the recom-
mended measures may not be relevant or feasible in
routine clinical practice. The topic of assessment in
the context of routine clinical practice warrants its
own consensus statement (see Szatmari, Offringa,
Butcher, & Monga, 2019) as recently developed by
ICHOM (2019). The inclusion of measures of both
symptoms and interference provides a bridge to
compare data from research trials and that obtained
in routine practice. Further evaluation of measures
to ensure appropriate and accurate clinical cutoffs
are available will be critical to enable both research-
ers and clinicians to use these measures to establish
whether clinically significant outcomes have been
obtained. We deliberately focused on general princi-
ples of assessment, rather than recommending
specific measurement tools, as we hope to influence
both trial reporting going forwards and how existing
data is used, for example, in meta-analyses. Finally,
we focused specifically on treatment outcome mea-
sures, however, going forwards a similar approach to
the consistent measurement of putative mainte-
nance mechanisms will benefit data sharing to
promote understanding of how treatments work
and how to improve them.
This paper describes the outcomes of discussions
from a working group that set out to develop a
common language and both core and aspirational
principles to promote greater consistency in report-
ing on trials of treatments for child and adolescent
anxiety disorders. The recommendations, sugges-
tions and templates that we have presented are not
intended to constrain researchers, but instead we
hope they will provide a mechanism to broaden and
expand our science by allowing us to bring treatment
datasets together from around the world in mean-
ingful ways. While we took a very deliberate focus on
treatment trials for anxiety disorders in children and
adolescents, we recognize that many of the issues
raised will have parallels in treatment trials for other
mental health problems in children and adolescents,
and we encourage others to take similar steps to
promote consistent reporting to ensure that the
integration of trial data will create far more than
the sum of its parts, allowing us to address over-
due questions in child and adolescent mental health
research, such as what works for whom and how.
Supporting information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article:
Table S1. Template for reporting remission outcomes.
Table S2. Template for reporting contextual character-
istics of the treatment.
Table S3. Template for reporting structural character-
istics of the treatment (as planned in the manual).
Table S4. Template with example of treatment content.
Table S5. Template for reporting dosage of treatment
received across groups.
Table S6. Template for reporting treatment and thera-
pist delivery time across groups.
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Key points
 Anxiety disorders in children and adolescence are common and cause substantial impairment to individuals
and their families.
 A large number of randomized controlled trials to evaluate treatments for anxiety disorders in children and
adolescents have been conducted, yet studies vary widely in the outcome measures they use and how they
report them, limiting conclusions that can be drawn from meta-analyses
 We convened a series of workshops for researchers, practitioners, young people and parents to develop a set
of guidelines to promote greater consistency in reporting on trials for treatments of anxiety disorders in
children and adolescents.
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